Integrating CD8+ T cell signatures with additional biomarkers—such as PD-L1 tumor expression, sPD-L1, TMB, myeloid lineage populations, neutrophil-to-lymphocyte ratio, and Th1/Th2 CD4+ T cells—may enhance predictive accuracy. Here, CD8A is linked to neoplasm.